Herbert Smith Freehills advises sponsors on Antengene’s HK$2.6 billion Hong Kong IPO / 史密夫斐尔律师事务所作为联席保荐人境外律师为德琪医药26亿港元IPO提供法律服务 Herbert Smith Freehills Global law firm

News Snapshot:

Antengene is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The company offers industry-leading R&D capabilities and a differentiated strategic approach to developing novel oncology therapies. The IPO was over-subscribed more than 264 times at the Hong Kong public offering, raised over HK$2.6 billion (US$335 million), and listed on 20 November 2020. The offering attracted 10 cornerstone investors that subscribed to shares worth approximately HK$1.39 billion in total (approximately US$179 million). “This year has been notable for the wave of healthcare listings in Hong Kong,” said Hong Kong partner Matt Emsley . “It is encouraging to see repeated...